Healthcare Triangle, Inc. — fact timeline

Healthcare Triangle, Inc. incurred senior notes of $4.235 million at 15% original issue discount maturing December 12, 2026.

“On June 12, 2026, Healthcare Triangle, Inc. (the “Company”) completed a private placement offering (the “Note Offering”) of its 15% original issue discount senior convertible promissory notes (the “Notes”) in the aggregate principal amount of $4.235 million for aggregate gross proceeds of approximately $3.6 million, before deducting placement agent fees and other related offering expenses.”

Healthcare Triangle, Inc. entered into Registration Rights Agreement with the Investor (effective 2026-06-12).

“Also on June 12, 2026, the Company entered into a Registration Rights Agreement with the Investor (the “Registration Rights Agreement” and, together with the Equity Purchase Agreement and the Warrant, the “Equity Line Transaction Documents”).”

Healthcare Triangle, Inc. entered into Equity Purchase Agreement with Hudson Global Ventures, LLC valued at $50,000,000 (effective 2026-06-12).

“On June 12, 2026, the Company entered into an Equity Purchase Agreement (the “Equity Purchase Agreement”) with Hudson Global Ventures, LLC, a Nevada limited liability company (the “Investor”).”

Healthcare Triangle, Inc. entered into Securities Purchase Agreement with the purchasers party thereto valued at $4.235 million aggregate principal amount (effective 2026-06-12).

“On June 12, 2026, Healthcare Triangle, Inc. (the “Company”) completed a private placement offering (the “Note Offering”) of its 15% original issue discount senior convertible promissory notes (the “Notes”) in the aggregate principal amount of $4.235 million for aggregate gross proceeds of approximately $3.6 million, before deducting placement agent fees and other related offering expenses. The Notes were issued pursuant to a Securities Purchase Agreement, dated as of June 12, 2026 (the “Securities Purchase Agreement”), by and among the Company and the purchasers party thereto.”

Healthcare Triangle, Inc. entered into Platform Development Agreement with SecureKloud Technologies Limited (effective 2026-03-31).

“On April 7, 2026, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), entered into a Platform Development Agreement (the “ Agreement ”) with SecureKloud Technologies Limited, an Indian corporation (“ SKL ”), as lead contractor, and Blockedge Technologies Inc., a subsidiary of SKL (“ Blockedge ”), as sub-contractor. The Agreement is made effective as of March 31, 2026.”

Healthcare Triangle, Inc. completed an acquisition involving CH 109, S.L., Ivan Montero Rebato and Maria Luisa Sanchez Fernandez.

“relating to the acquisition by Teyame AI Holdings Inc., the Company’s wholly owned subsidiary, of all of the outstanding equity interests of Teyamé 360 S.L. and Datono Mediación S.L. pursuant to that certain Share Purchase Agreement, dated January 22, 2026”

Healthcare Triangle, Inc. entered into Placement Agency Agreement with D. Boral Capital LLC (effective 2026-02-26).

“In connection with the Offering, the Company also entered into a placement agency agreement (the “Placement Agency Agreement”) with D. Boral Capital LLC (the “Placement Agent”), pursuant to which the Company paid the Placement Agent (i) a cash fee equal to 7% of the aggregate gross proceeds of the Offering, and (ii) reimbursed the Placement Agent for certain expenses and legal fees.”

Healthcare Triangle, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $3.95 million (effective 2026-02-26).

“On February 26, 2026, Healthcare Triangle, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (A) an aggregate of 421,553 shares (the “Shares”) of common stock, par value $0.00001 per share (the “Common Stock”), of the Company, at an offering price of $5.81 per share, and (B) 260,000 pre-funded warrants (the “Pre-Funded Warrants”) in lieu of shares of Common Stock, at an offering price of $5.80999 (such registered direct offering, the “Offering”) for aggregate gross proceeds of approximately $3.95 million, before deducting Offering expenses payable by the Company, including the Placement Agent’s commissions and fees.”

Healthcare Triangle, Inc. entered into Share Purchase Agreement with Teyame AI Holdings Inc., Teyame AI LLC, CH 109, S.L., Ivan Montero Rebato, Maria Luisa Sanchez Fernandez valued at up to $50.0 million (effective 2026-01-22).

“On January 22, 2026, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), entered into a Share Purchase Agreement (the “ Share Purchase Agreement ”), by and among (i) Teyame AI Holdings Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Buyer ”), (ii) the Company, (iii) Teyame AI LLC, a St Kitts and Nevis corporation (the “ Intermediary Seller ”), (iv) CH 109, S.L., a company incorporated in Spain (“ CH 109 ”), and (v) Ivan Montero Rebato and Maria Luisa Sanchez Fernandez (together with CH 109, S.L., the “ Original Sellers ”).”

Healthcare Triangle, Inc. entered into Advance Agreement with Teyame A.I. LLC valued at up to approximately $50.0 million (effective 2025-12-05).

“On December 5, 2025, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”) entered into a non-binding advance agreement (the “ Advance Agreement ”) with Teyame A.I. LLC, a St. Kitts and Nevis limited liability company (“ Teyame ”), in connection with a proposed acquisition by the Company of 100% of the equity interests of Teyame 360 S.L. and Datono Mediacion S.L.”

Healthcare Triangle, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $6,000,000 (effective 2025-11-20).

“On November 20, 2025, Healthcare Triangle, Inc., a Delaware corporation, (the “Company”), entered into a Securities Purchase Agreement (“Purchase Agreement”) with certain institutional investors (the “Investors”).”

Healthcare Triangle, Inc. issued convertible note to certain institutional investors for $6,000,000 purchase price for Initial Tranche principal amount of $7,500,000.

“(“Common Stock”). The closing of the first tranche was consummated on November 20, 2025, and the Company issued the initial Note for an aggregate original principal amount of $7,500,000 (the “Initial Tranche”). The Note issued in the Initial Tranche was sold to the Investors for a purchase price of $6,000,000, representing an original issue discount of twenty”

Healthcare Triangle, Inc. incurred convertible notes of $7,500,000 with institutional investors at 18% per annum maturing November 20, 2026.

“Under the Purchase Agreement, the Company has agreed to issue 20% original issue discount senior unsecured convertible promissory notes (“Notes”) in an aggregate original principal amount of up to $15,000,000, which will be convertible into shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”). The closing of the first tranche was consummated on November 20, 2025, and the Company issued the initial Note for an aggregate original principal amount of $7,500,000 (the “Initial Tranche”). The Note issued in the Initial Tranche was sold to the Investors for a purchase price of $6,000,000, representing an original issue discount of twenty percent (20%), and matures on November 20, 2026.”

Healthcare Triangle, Inc. issued warrant to holders of the Company’s warrants to purchase shares of the Company’s common stock issued on February 28, 2025.

“the information contained in Item 1.01 of this Current Report on Form 8-K and Exhibit 10.1 to this Current Report on Form 8-K regarding the Existing Warrants are incorporated herein by reference”

Healthcare Triangle, Inc. issued an aggregate of up to 1,429,528 shares of Common Stock of common stock to holders of the Company’s warrants to purchase shares of the Company’s common stock issued on February 28, 2025 for at the reduced exercise price of $2.00 per share.

“the Holders of the Existing Warrants agreed to exercise for cash the Existing Warrants to purchase an aggregate of up to 1,429,528 shares of Common Stock (the “Existing Warrant Shares”), at the reduced exercise price of $2.00 per share”

Healthcare Triangle, Inc. issued 2.0% of the number of New Warrant Shares issued in the offering of warrant to WallachBeth Capital, LLC.

“the Company agreed to issue to the designees of the Financial Advisor, warrants (“Advisor Warrants”) to purchase shares of Common Stock (the “Advisor Warrant Shares”), equal to approximately 2.0% of the number of New Warrant Shares issued in the offering”

Healthcare Triangle, Inc. issued up to 1,429,528 shares of Common Stock of warrant to holders of the Company’s warrants to purchase shares of the Company’s common stock issued on February 28, 2025 for aggregate gross proceeds of approximately $2.85 million.

“were consummated on October 2, 2025, October 3, 2025, and October 8, 2025 (together the “Closing Date”). The Company received aggregate gross proceeds of approximately $2.85 million, before deducting advisory fees and other expenses payable by the Company. In consideration of the Holders’ immediate exercise of the Existing Warrants in accordance with the”

Healthcare Triangle, Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5635(a)(1)).

“September 15, 2025, Healthcare Triangle, Inc. (the “Company”) received a letter from the Nasdaq Stock Market (“Nasdaq”) indicating that the Company had previously failed to comply with Nasdaq Listing Rule 5635(a)(1), which requires shareholder approval prior to the issuance of common stock representing 20% or more of the pre-transaction outstanding voting power or shares in connection with an acquisition. Nasdaq’s determination was based on the Company’s Form 8-K filed June 23, 2025, which disclosed that the Company agreed to issue approximately 345,622,120 shares of common stock (prior to adj”

Healthcare Triangle, Inc. completed an acquisition involving Niyama Healthcare, Inc. for $5.7 million (closed 2025-06-16).

“Price (as defined below) . The acquisition also closed on June 16, 2025. The total consideration for the acquisition, which is referred to herein as the “Purchase Price” is $5.7 million which includes: (1) $1.5 million in cash, of which $1.2 million is due on the Closing Date and $300,000 to be paid at the later of the satisfaction of certain withholding”

Healthcare Triangle, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

“May 30, 2025, the Company received notice from the Staff (the “May 30 Letter”) that the Staff had determined that as of May 29, 2025, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days triggering application of Listing Rule 5810(c)(3)(A)(iii) which states in part: if during any compliance period specified in Rule 5810(c)(3)(A), a company’s security has a closing bid price of $0.10 or less for ten consecutive trading days, the Listing Qualifications Department shall issue a Staff Delisting Determination under Rule 5810 with respect to that securit”

Healthcare Triangle, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 26, 2025, the Healthcare Triangle, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the bid price of its listed securities had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until August 25, 2025, to regain compliance with the Minimum Bid Price Requirement.”

Healthcare Triangle, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).

“May 20, 2025, Healthcare Triangle, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), stating that based on its review of the Company’s public filings with the Securities and Exchange Commission (the “SEC”), its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the Company’s issuance of securities pursuant to the Company’s private placement, dated February 27, 2025”

Healthcare Triangle, Inc. engaged SRCO Professional Corporation, Chartered Professional Accountants as its auditor.

“On April 11, 2025, the Company engaged SRCO Professional Corporation, Chartered Professional Accountants (the "New Auditor") as its independent PCAOB registered public accounting firm for the Company’s fiscal year ended December 31, 2025.”

Healthcare Triangle, Inc. dismissed M&K CPAS, PLLC as its auditor.

“On April 10, 2025 (the "Termination Date"), the board of directors of Healthcare Triangle, Inc. (the "Company") directed the Company to notify M&K CPAS, PLLC ("M&K") that the Company is dismissing M&K (the "Former Auditor") as the independent registered public accounting firm of the Company.”

Sujatha Ramesh was appointed as executive director at Healthcare Triangle, Inc..

“the Board appointed Ms. Sujatha Ramesh as an executive director of the Company, along with their current role as the Chief Operating Officer of the Company.”

Shibu Kizhakevilayil resigned as director at Healthcare Triangle, Inc..

“Mr. Shibu Kizhakevilayil resigned as a director of the Company, effective immediately.”

David Ayanoglou was appointed as Chief Financial Officer at Healthcare Triangle, Inc..

“the Board of Directors (the “Board”) of the Company appointed Mr. David Ayanoglou to serve as the Company’s Chief Financial Officer, effective immediately.”

Thyagarajan Ramachandran resigned as Chief Financial Officer at Healthcare Triangle, Inc..

“On April 8, 2025, Mr. Thyagarajan Ramachandran informed the Company that they had decided to resign from their position as the Chief Financial Officer of the Company, effective April 10, 2025, along with the appointment of Mr. David Ayanoglou as the new Chief Financial Officer of the Company.”

Sujatha Ramesh was appointed as Chief Operating Officer at Healthcare Triangle, Inc..

“On March 18, 2025, the Board of Directors (the “Board”) of the Healthcare Triangle, Inc. (the “Company”) appointed Ms. Sujatha Ramesh to serve as the Company’s Chief Operating Officer, effective immediately.”

Healthcare Triangle, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“February 28, 2025, the Company received net proceeds of $13.68 million from its $15.2 million private placement of units consisting of common stock or prefunded warrants and series A warrants and series B warrants (the “Private Offering”). As of February 28, 2025, the Company believes it is in compliance with the Minimum Equity Requirement as a result of receiving approximately $13.68 million in net proceeds from the Private Offering, after considering anticipated net losses through February 28, 2025. Nasdaq will continue to monitor the Company’s ongoing compliance with the Minimum Equity Requ”

Healthcare Triangle, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 26, 2025, Healthcare Triangle, Inc. (the “ Company ”) received written notice (the “ Bid Price Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that for the last 30 consecutive business days prior to the date of the Bid Price Notice, the closing bid price of the Company’s common stock was less than the $1.00 per share minimum bid price required for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(a)(2) (the “ Bid Price Rule ”). In accordance with Nasdaq Listing”

Healthcare Triangle, Inc. reported that prior financial statements should not be relied upon.

“On February 12, 2025, the Board of Directors of Healthcare Triangle, Inc. (the “Company”), upon the recommendation of the Audit Committee (the “Audit Committee”) of the Company resolved that the Company’s previously issued financial statements (the “Prior Financial Statements”) contained within its Annual Report on Form 10-K for the year ended December 31, 2023, originally filed on March 18, 2024, should no longer be relied upon due to errors in the Prior Financial Statements (the “Restatement”).”

Healthcare Triangle, Inc. received a nasdaq noncompliance notice notice regarding shareholders (rules 5620).

“January 14, 2025, Healthcare Triangle, Inc. (the “ Company ”), received a letter from Nasdaq (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules since it has not yet held an annual meeting of shareholders within twelve months of the Company’s fiscal year end and since the Nasdaq Hearings panel is currently considering the Company’s continued listing on based on another compliance matter, the Panel will include the Company’s annual meeting non-compliance as an additional basis for delisting. No annual meeting of stockholders was held in 2024 due primarily to t”

Healthcare Triangle, Inc. received a nasdaq noncompliance notice notice regarding shareholders.

“January 14, 2025, Healthcare Triangle, Inc. (the “ Company ”), received a letter from Nasdaq (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rules since it has not yet held an annual meet”

Healthcare Triangle, Inc.: Filed Certificate of Designations for Series B Convertible Preferred Stock, establishing preferences, limitations, and relative rights of the new series (effective 2024-10-22).

“On October 22, 2024, in relation to the Asset Transfer Agreement, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “ Series B Certificate of Designations ”) with the Secretary of State of the State of Delaware to establish the preferences, limitations and relative rights of the Series B Convertible Preferred Stock (the “ Series B Convertible Preferred Stock ”).”

Anand Kumar resigned as Interim Chief Executive Officer at Healthcare Triangle, Inc..

“On September 4, 2024, Anand Kumar, the Interim Chief Executive Officer (“CEO”) of the Company, resigned from his role as CEO, effective immediately to pursue other professional opportunities.”

Healthcare Triangle, Inc. engaged M&K CPAS, PLLC as its auditor.

“On May 8, 2024, M&K CPAS, PLLC (“M&K”) was appointed as the new independent registered public accounting firm for Healthcare Triangle, Inc.”

Healthcare Triangle, Inc. dismissed BF Borgers CPA PC as its auditor.

“On May 3, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of Healthcare Triangle, Inc., a Delaware corporation (or the “Company”) approved the dismissal of BF Borgers CPA PC (“BF Borgers”) as the Company’s independent registered public accounting firm.”

Healthcare Triangle, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 20, 2024, Healthcare Triangle, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its annual report on Form 10-K for the period ended December 31, 2023, the Company reported stockholders’ equity of $538,000, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the”

Anand Kumar was appointed as interim chief executive officer at Healthcare Triangle, Inc..

“On March 14, 2024, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), appointed Mr. Anand Kumar, as interim chief executive officer of the Company (the “ Interim CEO ”), effective March 15, 2024”

Healthcare Triangle, Inc. terminated Supplier Master Services Agreement with Guidant Global Inc. (effective 2024-02-04).

“On January 30, 2024, Devcool, Inc. (the "Supplier"), a wholly-owned subsidiary of the Healthcare Triangle, Inc. ("HCTI" or the "Company") received a letter from Guidant Global Inc. ("Guidant"), terminating the Supplier Master Services Agreement (the "Agreement") by and between Guidant and the Supplier, regarding the Supplier’s services to City of Hope National Medical Center, City of Hope Medical Foundations, Beckman Research Institute of the City of Hope, and City of Hope effective February 04, 2024.”

Lakshmanan Kannappan resigned as Director at Healthcare Triangle, Inc..

“On February 1, 2024, Mr. Lakshmanan Kannappan notified the Board of the Company of his resignation as a member of the Board of the Company, effective immediately.”

Healthcare Triangle, Inc. incurred convertible notes of $2,000,000 with institutional investor at 18% maturing 18 months after issuance.

“greement (the “ Purchase Agreement ”) with an institutional investor (the “ Investor ”), pursuant to which the Company agreed to issue to the Investor Senior Secured 15% Original Issue Discount Convertible Promissory Notes (the “ Notes ”)”

Healthcare Triangle, Inc. entered into Securities Purchase Agreement with institutional investor valued at Aggregate principal amount up to $5,200,000; gross proceeds up to $4,420,000 (effective 2023-12-28).

“On December 28, 2023, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Investor ”), pursuant to which the Company agreed to issue to the Investor Senior Secured 15% Original Issue Discount Convertible Promissory Notes (the “ Notes ”) in the aggregate principal amount of up to $5,200,000 which will result in gross proceeds to the Company in the amount of up to $4,420,000 due to the original issue discount, and warrants (the “ Warrants ”) to purchase a number of shares of the Company’s common stock (the “ Warrant Shares ”) equal to 50% of the face value of the Notes divided by the volume weighted average price, in three tranches (such transaction, the “ Private Placement ”).”

Healthcare Triangle, Inc. incurred convertible notes of $2,000,000 maturing 18 months after issuance.

“Under the first tranche of funding, which closed upon signing of the Purchase Agreement on December 28, 2023, the Company issued a Note to the Investor in the principal amount of $2,000,000 which resulted in gross proceeds to the Company of $1,700,000 and Warrants to purchase up to an aggregate of 357,500 Warrant Shares.”

Healthcare Triangle, Inc. entered into Securities Purchase Agreement with an institutional investor valued at up to $5,200,000 (effective 2023-12-28).

“On December 28, 2023, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Investor ”), pursuant to which the Company agreed to issue to the Investor Senior Secured 15% Original Issue Discount Convertible Promissory Notes (the “ Notes ”) in the aggregate principal amount of up to $5,200,000 which will result in gross proceeds to the Company in the amount of up to $4,420,000 due to the original issue discount, and warrants”

Paige Heaphy resigned as Director at Healthcare Triangle, Inc..

“On September 1, 2023, Ms. Heaphy notified the Board of the Company of her resignation as a member of the Board of the Company, effective upon the earlier of (1) September 1, 2023; or (2) the date their replacement is appointed as a member of the Board of Directors.”

Healthcare Triangle, Inc. reported a default on debt of $2,409,437 with Seacoast Business Funding, a division of Seacoast National Bank at 18%.

“fee payable by HCTI to Seacoast went from the Prime Rate (as defined in the Purchasing Agreement) to 18%. As of June 28, 2023, the Company has an outstanding payment balance of $2,409,437 under the Purchase Agreement. Section 6(h) of the Purchase Agreement requires the Company to obtain the written consent of Seacoast prior to obtaining any loans or advances. On”

Healthcare Triangle, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“May 31, 2023, Healthcare Triangle, Inc. (the “Company”) received a notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq has determined the Company did not regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by May 30, 2023, the deadline to regain compliance with the Rule pursuant to the notice the Company received from Nasdaq on December 1, 2022 (the “Extension Notice”), and therefore the”

Healthcare Triangle, Inc. reported a fiscal year change.

“Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. To the extent required by Item 5.03 of Form 8-K, the information contained in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference.”